Cargando…

Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy

The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated epithelial Cl(−) channel that, when defective, causes cystic fibrosis. Screening of a collection of 100,000 diverse small molecules revealed four novel chemical classes of CFTR inhibitors with K(i) < 10 μM,...

Descripción completa

Detalles Bibliográficos
Autores principales: Muanprasat, Chatchai, Sonawane, N.D., Salinas, Danieli, Taddei, Alessandro, Galietta, Luis J.V., Verkman, A.S.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2229623/
https://www.ncbi.nlm.nih.gov/pubmed/15277574
http://dx.doi.org/10.1085/jgp.200409059
_version_ 1782150171859091456
author Muanprasat, Chatchai
Sonawane, N.D.
Salinas, Danieli
Taddei, Alessandro
Galietta, Luis J.V.
Verkman, A.S.
author_facet Muanprasat, Chatchai
Sonawane, N.D.
Salinas, Danieli
Taddei, Alessandro
Galietta, Luis J.V.
Verkman, A.S.
author_sort Muanprasat, Chatchai
collection PubMed
description The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated epithelial Cl(−) channel that, when defective, causes cystic fibrosis. Screening of a collection of 100,000 diverse small molecules revealed four novel chemical classes of CFTR inhibitors with K(i) < 10 μM, one of which (glycine hydrazides) had many active structural analogues. Analysis of a series of synthesized glycine hydrazide analogues revealed maximal inhibitory potency for N-(2-naphthalenyl) and 3,5-dibromo-2,4-dihydroxyphenyl substituents. The compound N-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycine hydrazide (GlyH-101) reversibly inhibited CFTR Cl(−) conductance in <1 min. Whole-cell current measurements revealed voltage-dependent CFTR block by GlyH-101 with strong inward rectification, producing an increase in apparent inhibitory constant K(i) from 1.4 μM at +60 mV to 5.6 μM at −60 mV. Apparent potency was reduced by lowering extracellular Cl(−) concentration. Patch-clamp experiments indicated fast channel closures within bursts of channel openings, reducing mean channel open time from 264 to 13 ms (−60 mV holding potential, 5 μM GlyH-101). GlyH-101 inhibitory potency was independent of pH from 6.5–8.0, where it exists predominantly as a monovalent anion with solubility ∼1 mM in water. Topical GlyH-101 (10 μM) in mice rapidly and reversibly inhibited forskolin-induced hyperpolarization in nasal potential differences. In a closed-loop model of cholera, intraluminal GlyH-101 (2.5 μg) reduced by ∼80% cholera toxin–induced intestinal fluid secretion. Compared with the thiazolidinone CFTR inhibitor CFTR(inh)-172, GlyH-101 has substantially greater water solubility and rapidity of action, and a novel inhibition mechanism involving occlusion near the external pore entrance. Glycine hydrazides may be useful as probes of CFTR pore structure, in creating animal models of CF, and as antidiarrheals in enterotoxic-mediated secretory diarrheas.
format Text
id pubmed-2229623
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22296232008-03-21 Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy Muanprasat, Chatchai Sonawane, N.D. Salinas, Danieli Taddei, Alessandro Galietta, Luis J.V. Verkman, A.S. J Gen Physiol Article The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated epithelial Cl(−) channel that, when defective, causes cystic fibrosis. Screening of a collection of 100,000 diverse small molecules revealed four novel chemical classes of CFTR inhibitors with K(i) < 10 μM, one of which (glycine hydrazides) had many active structural analogues. Analysis of a series of synthesized glycine hydrazide analogues revealed maximal inhibitory potency for N-(2-naphthalenyl) and 3,5-dibromo-2,4-dihydroxyphenyl substituents. The compound N-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycine hydrazide (GlyH-101) reversibly inhibited CFTR Cl(−) conductance in <1 min. Whole-cell current measurements revealed voltage-dependent CFTR block by GlyH-101 with strong inward rectification, producing an increase in apparent inhibitory constant K(i) from 1.4 μM at +60 mV to 5.6 μM at −60 mV. Apparent potency was reduced by lowering extracellular Cl(−) concentration. Patch-clamp experiments indicated fast channel closures within bursts of channel openings, reducing mean channel open time from 264 to 13 ms (−60 mV holding potential, 5 μM GlyH-101). GlyH-101 inhibitory potency was independent of pH from 6.5–8.0, where it exists predominantly as a monovalent anion with solubility ∼1 mM in water. Topical GlyH-101 (10 μM) in mice rapidly and reversibly inhibited forskolin-induced hyperpolarization in nasal potential differences. In a closed-loop model of cholera, intraluminal GlyH-101 (2.5 μg) reduced by ∼80% cholera toxin–induced intestinal fluid secretion. Compared with the thiazolidinone CFTR inhibitor CFTR(inh)-172, GlyH-101 has substantially greater water solubility and rapidity of action, and a novel inhibition mechanism involving occlusion near the external pore entrance. Glycine hydrazides may be useful as probes of CFTR pore structure, in creating animal models of CF, and as antidiarrheals in enterotoxic-mediated secretory diarrheas. The Rockefeller University Press 2004-08 /pmc/articles/PMC2229623/ /pubmed/15277574 http://dx.doi.org/10.1085/jgp.200409059 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Muanprasat, Chatchai
Sonawane, N.D.
Salinas, Danieli
Taddei, Alessandro
Galietta, Luis J.V.
Verkman, A.S.
Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title_full Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title_fullStr Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title_full_unstemmed Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title_short Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy
title_sort discovery of glycine hydrazide pore-occluding cftr inhibitors: mechanism, structure–activity analysis, and in vivo efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2229623/
https://www.ncbi.nlm.nih.gov/pubmed/15277574
http://dx.doi.org/10.1085/jgp.200409059
work_keys_str_mv AT muanprasatchatchai discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy
AT sonawanend discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy
AT salinasdanieli discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy
AT taddeialessandro discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy
AT galiettaluisjv discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy
AT verkmanas discoveryofglycinehydrazideporeoccludingcftrinhibitorsmechanismstructureactivityanalysisandinvivoefficacy